In the BioHarmony Drug Report Database

"Preview" Icon

Turoctocog alfa

NovoEight (turoctocog alfa) is a protein pharmaceutical. Turoctocog alfa was first approved as NovoEight on 2013-11-13. It is used to treat factor VII deficiency, hemophilia a, hemorrhage, and von willebrand diseases in the USA. It has been approved in Europe to treat hemophilia a.

 

Trade Name

 

NovoEight
 

Common Name

 

turoctocog alfa
 

ChEMBL ID

 

CHEMBL2108286
 

Indication

 

factor vii deficiency, hemophilia a, hemorrhage, von willebrand diseases
 

Drug Class

 

Image (chem structure or protein)

Turoctocog alfa structure rendering